Xenpozyme Injection, Powder, Lyophilized, For Solution
Product Images NDC 58468-0050

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Xenpozyme (NDC 58468-0050). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genzyme Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Xenpozyme 01)

This appears to be a table showing the number of patients who were given either a placebo or a medication called XENPOZYME (which appears to be spelled out in capital letters) over a period of 104 weeks. The table contains columns for each of the five time points (Baseline, Week26, Week52, Week80, and Week104) and rows for each group of patients (those given placebo, and those given XENPOZYME). The number of patients in each group is shown for each time point. The meaning or context for the numbers is not clear.*

FDA Label Image

Figure 2 (Xenpozyme 02)

FDA Label Image

Principal Display Panel (20 mg Vial Carton)

This is a description of Menpozyme™, which is a medication that is administered by injection. Each vial of Menpozyme™ contains 20 mg of olipudase alfa-rpcp and is reconstituted with 5.1 mL of sterile water for injection, USP to a single-dose solution. It is manufactured by Genzyme Corporation and is stored refrigerated. For more information on dosage and storage, see prescribing information.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.